88 related articles for article (PubMed ID: 1979347)
41. Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu.
Taylor P; Gerder M; Moros Z; Feldmann M
Cancer Immunol Immunother; 1996 Mar; 42(3):179-84. PubMed ID: 8640846
[TBL] [Abstract][Full Text] [Related]
42. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids.
Sias PE; Kotts CE; Vetterlein D; Shepard M; Wong WL
J Immunol Methods; 1990 Aug; 132(1):73-80. PubMed ID: 1975263
[TBL] [Abstract][Full Text] [Related]
43. p185HER2 signal transduction in breast cancer cells.
Scott GK; Dodson JM; Montgomery PA; Johnson RM; Sarup JC; Wong WL; Ullrich A; Shepard HM; Benz CC
J Biol Chem; 1991 Aug; 266(22):14300-5. PubMed ID: 1677643
[TBL] [Abstract][Full Text] [Related]
44. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells.
Kumar R; Shepard HM; Mendelsohn J
Mol Cell Biol; 1991 Feb; 11(2):979-86. PubMed ID: 1671297
[TBL] [Abstract][Full Text] [Related]
45. The role of erbB-2 and its ligands in growth control of malignant breast epithelium.
Lupu R; Dickson RB; Lippman ME
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):229-36. PubMed ID: 1356015
[TBL] [Abstract][Full Text] [Related]
46. A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ.
Zhang H; Lam L; Nagai Y; Zhu Z; Chen X; Ji MQ; Greene MI
Oncoimmunology; 2018; 7(4):e1300739. PubMed ID: 29632709
[TBL] [Abstract][Full Text] [Related]
47. HER2/neu: a target for breast cancer therapy.
Zwick E; Wallasch C; Ullrich A
Breast Dis; 2000; 11():7-18. PubMed ID: 15687589
[TBL] [Abstract][Full Text] [Related]
48. Active specific immunotherapy against adenocarcinomas.
MacLean GD; Reddish MA; Bowen-Yacyshyn MB; Poppema S; Longenecker BM
Cancer Invest; 1994; 12(1):46-56. PubMed ID: 7506634
[No Abstract] [Full Text] [Related]
49. Exploring the Molecular Mechanism of the Drug-Treated Breast Cancer Based on Gene Expression Microarray.
Alshabi AM; ; Shaikh IA; Vastrad C
Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31311202
[No Abstract] [Full Text] [Related]
50. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2.
Maadi H; Nami B; Tong J; Li G; Wang Z
BMC Cancer; 2018 Mar; 18(1):238. PubMed ID: 29490608
[TBL] [Abstract][Full Text] [Related]
51. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.
Chung A; Choi M; Han BC; Bose S; Zhang X; Medina-Kauwe L; Sims J; Murali R; Taguiam M; Varda M; Schiff R; Giuliano A; Cui X
Clin Breast Cancer; 2015 Dec; 15(6):448-457.e2. PubMed ID: 26248960
[TBL] [Abstract][Full Text] [Related]
52. Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.
Chung A; Cui X; Audeh W; Giuliano A
Clin Breast Cancer; 2013 Aug; 13(4):223-32. PubMed ID: 23829888
[TBL] [Abstract][Full Text] [Related]
53. Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis.
Hu J; Liu X; Hughes D; Esteva FJ; Liu B; Chandra J; Li S
PLoS One; 2011; 6(8):e23270. PubMed ID: 21853100
[TBL] [Abstract][Full Text] [Related]
54. Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model.
Felizardo TC; Wang JC; McGray RA; Evelegh C; Spaner DE; Fowler DH; Bramson JL; Medin JA
Gene Ther; 2011 Oct; 18(10):986-95. PubMed ID: 21490686
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
[TBL] [Abstract][Full Text] [Related]
56. Cancer therapy with bispecific antibodies: Clinical experience.
Thakur A; Lum LG
Curr Opin Mol Ther; 2010 Jun; 12(3):340-9. PubMed ID: 20521223
[TBL] [Abstract][Full Text] [Related]
57. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
Campbell MJ; Wollish WS; Lobo M; Esserman LJ
In Vitro Cell Dev Biol Anim; 2002 Jun; 38(6):326-33. PubMed ID: 12513120
[TBL] [Abstract][Full Text] [Related]
58. Heregulins and the ErbB-2/3/4 receptors in gliomas.
Westphal M; Meima L; Szonyi E; Lofgren J; Meissner H; Hamel W; Nikolics K; Sliwkowski MX
J Neurooncol; 1997 Dec; 35(3):335-46. PubMed ID: 9440030
[TBL] [Abstract][Full Text] [Related]
59. Remodeling domain interfaces to enhance heterodimer formation.
Zhu Z; Presta LG; Zapata G; Carter P
Protein Sci; 1997 Apr; 6(4):781-8. PubMed ID: 9098887
[TBL] [Abstract][Full Text] [Related]
60. Targeted tumor killing via an intracellular antibody against erbB-2.
Deshane J; Siegal GP; Alvarez RD; Wang MH; Feng M; Cabrera G; Liu T; Kay M; Curiel DT
J Clin Invest; 1995 Dec; 96(6):2980-9. PubMed ID: 8675670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
